Clinical and cerebrospinal fluid changes in parkinsonian patients treated with L-3,4-dihydroxyphenylalanine (L-dopa).
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage* / Q000134:cerebrospinal fluid; D004298:Dopamine / Q000134:cerebrospinal fluid; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000134:cerebrospinal fluid; D010300:Parkinson Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D010648:Phenylacetates / Q000134:cerebrospinal fluid; D013268:Stimulation, Chemical; D013566:Sympathomimetics / Q000008:administration & dosage
D010648:Phenylacetates; D013566:Sympathomimetics; D004295:Dihydroxyphenylalanine; D004298:Dopamine; D009638:Norepinephrine